168 related articles for article (PubMed ID: 19307461)
1. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
Hou G; Dick R; Brewer GJ
Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
[TBL] [Abstract][Full Text] [Related]
2. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
3. Tetrathiomolybdate therapy protects against concanavalin a and carbon tetrachloride hepatic damage in mice.
Askari FK; Dick R; Mao M; Brewer GJ
Exp Biol Med (Maywood); 2004 Sep; 229(8):857-63. PubMed ID: 15337842
[TBL] [Abstract][Full Text] [Related]
4. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Brewer GJ
Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
[TBL] [Abstract][Full Text] [Related]
6. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
George GN; Pickering IJ; Harris HH; Gailer J; Klein D; Lichtmannegger J; Summer KH
J Am Chem Soc; 2003 Feb; 125(7):1704-5. PubMed ID: 12580588
[TBL] [Abstract][Full Text] [Related]
7. Less reversal of liver fibrosis after prolonged carbon tetrachloride injection.
Lee HS; Huang GT; Chen CH; Chiou LL; Lee CC; Yang PM; Chen DS; Sheu JC
Hepatogastroenterology; 2001; 48(41):1312-5. PubMed ID: 11677953
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
Hou G; Abrams GD; Dick R; Brewer GJ
Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
[TBL] [Abstract][Full Text] [Related]
10. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.
Brewer GJ; Dick R; Zeng C; Hou G
J Inorg Biochem; 2006 May; 100(5-6):927-30. PubMed ID: 16321443
[TBL] [Abstract][Full Text] [Related]
11. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
Brewer GJ
J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
[TBL] [Abstract][Full Text] [Related]
12. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
[TBL] [Abstract][Full Text] [Related]
13. Newly proposed fibrosis staging criterion for assessing carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents.
Zhao XY; Wang BE; Li XM; Wang TL
Pathol Int; 2008 Sep; 58(9):580-8. PubMed ID: 18801073
[TBL] [Abstract][Full Text] [Related]
14. Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions.
Gardner JL; Turner SM; Bautista A; Lindwall G; Awada M; Hellerstein MK
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1695-705. PubMed ID: 17347453
[TBL] [Abstract][Full Text] [Related]
15. The risks of free copper in the body and the development of useful anticopper drugs.
Brewer GJ
Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):727-32. PubMed ID: 18827576
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
17. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
Zhang L; Lichtmannegger J; Summer KH; Webb S; Pickering IJ; George GN
Biochemistry; 2009 Feb; 48(5):891-7. PubMed ID: 19146437
[TBL] [Abstract][Full Text] [Related]
18. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
Brewer GJ; Dick RD; Yuzbasiyan-Gurkin V; Tankanow R; Young AB; Kluin KJ
Arch Neurol; 1991 Jan; 48(1):42-7. PubMed ID: 1986725
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
